GlucoMe received the CE Mark’s for its new Decision Support System (DSS), algorithm-based software that assists physicians to ensure optimal oral drug dosage for patients with Type 2 diabetes.
The cloud-based solution enables physicians to personalize management of the disease. In pilot studies, the software achieved similar medication recommendations to endocrinologists. The algorithm generated medication recommendations that were 98 percent in agreement with endocrinologists versus 82 percent agreement with the general practitioners.
The GlucoMe DSS can be either integrated into third-party products or can be directly operated from GlucoMe's Digital Diabetes Management platform.